Understanding risk in pharmaceutical supply chains
The ReMediES (Reconfiguring Medicines End-to-end Supply) project - involving 22 industrial partners comprising global pharmaceutical companies, major contract manufacturing organisations, equipment manufacturers, and logistics specialists – examined future pharmaceutical supply chains supported by novel technology. These technology interventions spanned the end-to-end pharmaceutical supply chain: R&D, Primary Manufacturing, Secondary Manufacturing, and Distribution to patients. The ReMediES project delivered outputs that are captured in Badman and Srai (2018) – see academic references at the end of this document. This briefing sets out the key outputs emerging from the strand of activity linked specifically to the management of pharmaceutical supply risk.